Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Status:
Withdrawn
Trial end date:
2000-04-26
Target enrollment:
Participant gender:
Summary
Current therapies for Recurrent or Refractory Waldenstrom's Macroglobulinemia provide very
limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest
that it may prove beneficial in the treatment of Recurrent or Refractory Waldenstrom's
Macroglobulinemia.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Recurrent or Refractory Waldenstrom's
Macroglobulinemia.